ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02632448
Recruitment Status : Recruiting
First Posted : December 16, 2015
Last Update Posted : July 31, 2018
Sponsor:
Information provided by (Responsible Party):
Esperas Pharma Inc.

Brief Summary:
The main purpose of this two-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumors Colorectal Cancer Breast Cancer Ovarian Cancer Colon Cancer Rectal Cancer Neoplasms Endometrial Cancer Soft Tissue Sarcoma Drug: LY2880070 Drug: Gemcitabine Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 143 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Study Start Date : May 2016
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
Experimental: Part A: LY2880070
Multiple oral doses of LY2880070 ranging from 10-400 milligrams (mg) per day (or higher), during 21-day cycles
Drug: LY2880070
Capsules

Experimental: Part A: LY2880070 with Gemcitabine
Multiple oral doses of LY2880070, and Gemcitabine administered intravenously on two or three days of each 21-day cycle
Drug: LY2880070
Capsules

Drug: Gemcitabine
50 to 600 milligrams per square meter of body surface area (mg/m2)
Other Name: Gemzar

Experimental: Part A: LY2880070 (Metabolism Phenotype)
Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers
Drug: LY2880070
Capsules

Experimental: Part B: LY2880070 (Breast)
Multiple oral doses of LY2880070 ranging from 10-400 milligrams (mg) per day (or higher), during 21-day cycles
Drug: LY2880070
Capsules

Experimental: Part B: LY2880070 (Colorectal)
Multiple oral doses of LY2880070 ranging from 10-400 milligrams (mg) per day (or higher), during 21-day cycles
Drug: LY2880070
Capsules

Experimental: Part B: LY2880070 with Gemcitabine (Ovarian, Endometrial, STS)
Multiple oral doses of LY2880070, and Gemcitabine administered intravenously on two or three days of each 21-day cycle
Drug: LY2880070
Capsules

Drug: Gemcitabine
50 to 600 milligrams per square meter of body surface area (mg/m2)
Other Name: Gemzar




Primary Outcome Measures :
  1. Maximum Tolerated Dose [ Time Frame: Baseline through Cycle 1 (Estimated up to 21 days) ]

Secondary Outcome Measures :
  1. Number of dose limiting toxicities (DLTs) [ Time Frame: Baseline through Cycle 1 (Estimated up to 21 days) ]
  2. Area under the plasma concentration versus time curve from time zero to 24 hours post-dose (AUC0-24) [ Time Frame: Baseline to 24-hours post dose (up to Day 20 in Cycle 1) ]
  3. Peak plasma concentration (Cmax) [ Time Frame: Baseline to 24 hours post-dose (up to Day 20 in Cycle 1) ]
  4. Time to reach maximum plasma concentration (tmax) [ Time Frame: Baseline to 24 hours post dose (up to Day 20 in Cycle 1) ]
  5. Change from baseline in white blood cell count [ Time Frame: Baseline to 24 hours post dose (up to Day 20 in Cycle 1) ]
  6. Change from baseline in neutrophil count [ Time Frame: Baseline to 24 hours post dose (up to Day 20 in Cycle 1) ]
  7. Change from baseline in lymphocyte count [ Time Frame: Baseline to 24 hours post dose (up to Day 20 in Cycle 1) ]
  8. Number of participants with tumor response (objective response rate) as measured by the Response Evaluable Criteria in Solid Tumors (RECIST v.1.1) [ Time Frame: Baseline to study completion (estimated up to 4 years) ]
  9. Duration of objective response [ Time Frame: Baseline to study completion (estimated up to 4 years) ]
  10. Best response [ Time Frame: Baseline to study completion (estimated up to 4 years) ]
  11. Progression free survival [ Time Frame: Baseline to study completion (estimated up to 4 years) ]
  12. Overall survival [ Time Frame: Baseline up to 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
  • Have an estimated life expectancy of greater than or equal to (≥)12 weeks
  • Have adequate organ function
  • Have received 1-4 prior systemic therapies for locally advanced or metastatic disease
  • Agree to use medically approved contraceptives during the study and for 3 months following the last study treatment
  • All females must have a negative serum pregnancy test result, and females of child-bearing potential must have a negative urine pregnancy test result, prior to the first study treatment
  • Have tumor lesions considered measurable by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
  • Must be, in the judgment of the investigator, an appropriate candidate for experimental therapy, and no standard therapy would confer clinical benefit
  • For Part A

    • Must have evidence of cancer (solid tumors, excluding glioblastoma and primary brain tumor) that is advanced or metastatic
    • For the Metabolism Phenotype Arm in Part A, participants must have a Cytochrome P450 (CYP2D6) poor metabolizer phenotype
  • For Part B

    • Have advanced or metastatic colorectal cancer, triple negative breast cancer (per American Society of Clinical Oncology-College of American Pathology guidelines), or epithelial ovarian cancer

      • Recurrent/refractory Triple Negative Breast Cancer (TNBC) is defined as breast cancer that expresses <1% estrogen receptor (ER) and <1% progesterone receptor (PR) and is Her2 negative
    • Participants with ovarian cancer:

      • Must be eligible to receive Gemcitabine (GEM) and not refractory to GEM/carboplatin
      • May have received GEM as previous therapy under some circumstances, but must have completed the last GEM regimen at least 12 months prior to this study
    • Participants with endometrial cancer:

      • Must have histologically confirmed endometrial cancer that is metastatic or locally advanced
      • Must have failed at least 1 prior chemotherapy
    • Participants with soft tissue sarcoma (STS):

      • Must have histologically confirmed STS that is metastatic or locally advanced
      • Participants with gastrointestinal stromal tumors (GIST) must have failed a KIT inhibitor
      • Must have failed at least 1 prior chemotherapy

Exclusion Criteria:

  • Have received treatment with an investigational drug which has not received regulatory approval within 21 days of first study treatment
  • Have symptomatic central nervous system (CNS) metastasis
  • Females who are pregnant or nursing
  • Have known positive test results of human immunodeficiency virus, or have chronic active hepatitis A, B or C
  • Have a corrected QT interval (QTcB) greater than (>) 470 milliseconds (msec) (female) or >450 msec (male), or a history of congenital long QT syndrome
  • Have had a bone marrow transplant
  • Have participated in this study, or are currently enrolled in another clinical study of an investigational medicinal product
  • Have had radiation therapy to >25% of bone marrow
  • For Part B

    • Have a history of another active cancer within the past year, except cervical cancer in situ, in situ carcinoma of the bladder, basal cell carcinoma of the skin, or another in situ carcinoma that is considered cured

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02632448


Contacts
Contact: Esperas Pharma Inc.

Locations
Canada, Alberta
Cross Cancer Institute Recruiting
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Bonnie Chalmers    (780) 432-8248      
Principal Investigator: Quincy Chu         
Canada, Ontario
Ottawa Hospital Cancer Centre Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Deborah Keller    (613) 247-3518    djonker@toh.on.ca   
Principal Investigator: Derek Jonker         
University Health Network - Princess Margaret Hospital Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Amit Oza    416-946-4501 ext 2818      
Principal Investigator: Amit Oza         
Canada, Quebec
Jewish General Hospital Recruiting
Montreal, Quebec, Canada, H3T 1E2
Contact: Wilson Miller    514-340-8222      
Principal Investigator: Wilson Miller         
McGill University Health Centre Recruiting
Montreal, Quebec, Canada, H4A 3J1
Contact: Nathaniel Bouganim    514-934-1934 ext 35800      
Principal Investigator: Nathaniel Bouganim         
Sponsors and Collaborators
Esperas Pharma Inc.
Investigators
Study Director: Email: choruspharma@lists.lilly.com Esperas Pharma Inc.

Responsible Party: Esperas Pharma Inc.
ClinicalTrials.gov Identifier: NCT02632448     History of Changes
Other Study ID Numbers: ESPS-001
First Posted: December 16, 2015    Key Record Dates
Last Update Posted: July 31, 2018
Last Verified: July 2018

Keywords provided by Esperas Pharma Inc.:
Metastatic cancer
Advanced cancer
Recurrent cancer
Colorectal neoplasms
Triple negative breast cancer
Ovarian neoplasms
Colon neoplasms
Rectal neoplasms
Triple negative breast neoplasms
Gastrointestinal stromal tumor

Additional relevant MeSH terms:
Neoplasms
Colorectal Neoplasms
Sarcoma
Endometrial Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Diseases
Genital Diseases, Female
Neoplastic Processes
Pathologic Processes
Gemcitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents